The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of gemcitabine (G), cisplatin (C), and nab-paclitaxel (N) in advanced biliary tract cancers (aBTCs).
 
Rachna T. Shroff
Stock and Other Ownership Interests - Celgene
Consulting or Advisory Role - Agios; Amgen; Celgene; Clovis Oncology; Codiak Biosciences
Research Funding - Agios; Celgene; Lilly
Travel, Accommodations, Expenses - Amgen; Celgene; Codiak Biosciences
 
Mitesh J. Borad
No Relationships to Disclose
 
Lianchun Xiao
No Relationships to Disclose
 
Ahmed Omar Kaseb
No Relationships to Disclose
 
Gauri R. Varadhachary
Employment - Fannin Partners (I)
Leadership - Fannin Partners (I); Pulmotect (I)
Stock and Other Ownership Interests - Fannin Partners (I)
Honoraria - Celgene; Merrimack; Momenta Pharmaceuticals; Rexahn Pharmaceuticals
Consulting or Advisory Role - Celgene; Merrimack; Momenta Pharmaceuticals; Rexahn Pharmaceuticals
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - Spouse is an inventor of use patents relating to recombinant human lactoferrin. The molecule is no longer in development and patents are being allowed to lapse as payments come due. (I); Spouse is inventor on a pending patent for an ELISA diagnostic platform. Not related to my area of research. (I)
Travel, Accommodations, Expenses - Celgene and Merrimack
 
Robert A. Wolff
No Relationships to Disclose
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - Genentech (Inst)
 
Michiko Iwasaki
No Relationships to Disclose
 
Peter Masci
No Relationships to Disclose
 
Ramesh K. Ramanathan
Honoraria - Cerulean Pharma; Insys Therapeutics; Novocure; Pharmacyclics; Taiho Pharmaceutical
Consulting or Advisory Role - Cerulean Pharma; Insys Therapeutics; Novocure; Pharmacyclics
Research Funding - Abbvie (Inst); Bayer (Inst); Berg Pharma (Inst); Biomarin (Inst); Boston Biomedical (Inst); Celgene (Inst); Halozyme (Inst); Merck/Schering Plough (Inst); Merrimack (Inst); Superlab Far East (Inst); Tekmira (Inst); Verastem (Inst)
 
Daniel H. Ahn
Consulting or Advisory Role - Celltrion (I); Merrimack
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Glenmark; Lilly; Merrimack; NCCN; Regeneron; Research to Practice; Taiho Pharmaceutical
Research Funding - NCCN; NCI; Oncolytics
Expert Testimony - Helsinn Therapeutics
Other Relationship - ARMO BioSciences; Exelixis; Exelixis; Merck; Polaris; Sillajen
 
Milind M. Javle
No Relationships to Disclose